25
|
Insulin Like Growth Factor-1 (IGF-1)
|
Protein
|
Humans
|
Dowregulated (Preintervention: 232.7 ± 20.6 ng/mL Vs Postintervention: 16.92 ± 23.3 ng/mL)
|
Predictive
|
Prostate Cancer patients pre and post treatment with Lycopene
|
p=0.0002
|
Plasma
|
11489752
|
26
|
Insulin Like Growth Factor Binding Protein 3 (IGFBP-3)
|
Protein
|
Humans
|
Dowregulated (Preintervention: 5230 ± 244 ng/mL Vs Postintervention: 3924 ± 298 ng/mL)
|
Predictive
|
Prostate Cancer patients pre and post treatment with Lycopene
|
p=0.0002
|
Plasma
|
11489752
|
403
|
Ki-67
|
Protein
|
Humans
|
Downregulated with Flaxseed supplemented Diet [ Control Diet: 3.23 (95% CI: 2.42-3.92), Flaxseed Supplementation: 1.66 (95% CI: 1.13-2.64)]
|
Predictive
|
Controls Vs Flaxseed Supplementation in Patients with PCa
|
p=0.0013
|
Tissue
|
19064574
|
404
|
Total cholesterol
|
Metabolites
|
Humans
|
Downregulated with Low Fat Diet [ Control Diet: 196 (95% CI: 180-226), Low Fat Diet: 182 (95% CI: 161-192)]
|
Predictive
|
Controls Vs Low Fat Supplementation in patients with PCa
|
p = 0.048
|
Blood
|
19064574
|
405
|
Low-density cholesterol
|
Metabolites
|
Humans
|
Downregulated with Low Fat Diet [ Control Diet: 111 (95% CI: 90-128), Low Fat Diet: 105 (95% CI: 90-124)]
|
Predictive
|
Controls Vs Low Fat Supplementation in patients with PCa
|
p=0.032
|
Blood
|
19064574
|
456
|
MIC-1 (Macrophage inhibitory cytokine 1)
|
Protein
|
Humans
|
Downregulated after one round of chemotherapy
|
Predictive
|
Metastatic HRPC patients Pre Vs Post One round of Docetaxel chemotherapy
|
p=0.02
|
Blood
|
19773444
|
457
|
MIC-1 (Macrophage inhibitory cytokine 1)
|
Protein
|
Humans
|
Downregulated after one round of chemotherapy
|
Predictive
|
Overall survival Vs No survival in patients Post One round of Docetaxel chemotherapy
|
p=0.002
|
Blood
|
19773444
|
462
|
Hepatocyte Growth Factor (HGF)
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(18.9%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p<0.001
|
Serum
|
19542190
|
463
|
Vascular Endothelial Growth Factor (VEGF)
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(9.9%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p=0.032
|
Serum
|
19542190
|
464
|
Insulin Like Growth Factor (IGF-I)
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(10.4%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p=0.012
|
Serum
|
19542190
|
465
|
IGF Binding Protein-3 (IGFBP-3)
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(11%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p=0.024
|
Serum
|
19542190
|
466
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(7.9%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p=0.009
|
Serum
|
19542190
|
467
|
IGF-I/IGFBP-3
|
Protein
|
Humans
|
Downregulated after Polyphenon E treatment(3.4%)
|
Predictive
|
Before Vs After Polyphenon E treatment
|
p=0.028
|
Serum
|
19542190
|
592
|
placental growth factor (PIGF)
|
Protein
|
Humans
|
Downregulated in Docetaxel + Imatinib arm
|
Predictive
|
Docetaxel + placebo VS Docetaxel + imatinib
|
p<0.001
|
Plasma
|
21323568
|
593
|
soluble c-kit
|
Protein
|
Humans
|
Downregulated in Docetaxel + Imatinib arm
|
Predictive
|
Docetaxel + placebo VS Docetaxel + imatinib
|
p<0.001
|
Plasma
|
21323568
|
594
|
VEGF
|
Protein
|
Humans
|
Downregulated in Docetaxel + Imatinib arm
|
Predictive
|
Docetaxel + placebo VS Docetaxel + imatinib
|
p<0.001
|
Plasma
|
21323568
|
595
|
sVEGFR1
|
Protein
|
Humans
|
Downregulated in Docetaxel + Imatinib arm
|
Predictive
|
Docetaxel + placebo VS Docetaxel + imatinib
|
p=0.001
|
Plasma
|
21323568
|
674
|
Circulating Tumor Cells (Base Line)
|
Others
|
Humans
|
NA
|
Predictive
|
Progression to Hormone-sensitive Prostate Cancer after ADT
|
p<0.001
|
Blood
|
21705286
|
793
|
Cholesterol
|
Lipid
|
Humans
|
Upregulated in Fish Oil Diet
|
Predictive
|
Change in Western Diet VS Change in Fish Oil Diet in Patients with PCa
|
0.005
|
Serum
|
22027686
|
794
|
Triglycerides
|
Lipid
|
Humans
|
Upregulated in Fish Oil Diet
|
Predictive
|
Change in Western Diet VS Change in Fish Oil Diet in Patients with PCa
|
p < 0.001
|
Serum
|
22027686
|
802
|
RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; SNCA; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; ALAS2; CAMP; LCN2; OLFM4; DEFA3; DEFA1; DEFA1; DEFA1; ERAF; CA1; HBD; DEFA1;
|
mRNA
|
Humans
|
Upregulated Postvaccine treatment: [RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; CAMP; LCN2; OLFM4; DEFA3; DEFA1;ERAF; CA1; HBD;]
|
Predictive
|
Short Term Survival Pre Vs Post Vaccination
|
p< 0.008
|
Blood
|
22071976
|
858
|
basic fibroblast growth factor (bFGF)
|
Protein
|
Humans
|
Upregulated in Treatment Group: [Treatment: 32 (25–71) Vs Control : 11 (8–14)]
|
Predictive
|
ADT Treatment Vs No Treatment
|
p=0.0006
|
Plasma
|
22302227
|
859
|
Interleukin 1 (IL-1β)
|
Protein
|
Humans
|
Upregulated in Treatment Group [Treatment:0.56 (0.45–0.90) Vs Control : 0.34 (0.25–0.52)]
|
Predictive
|
ADT Treatment Vs No Treatment
|
p=0.026
|
Plasma
|
22302227
|
860
|
Interleukin 8 (IL-8)
|
Protein
|
Humans
|
Upregulated in Treatment Group (Treatment: 5.7 (3.8–7.7) Vs Control : 2.2 (1.6–2.8) )
|
Predictive
|
ADT Treatment Vs No Treatment
|
p=0.0001
|
Plasma
|
22302227
|
861
|
stromal cell–derived factor 1α (SDF-1α)
|
Protein
|
Humans
|
Upregulated in Treatment Group (Treatment: 2,294 (1,775–2,671) Vs Control : 1,736 (1,577–1,842) )
|
Predictive
|
ADT Treatment Vs No Treatment
|
p=0.023
|
Plasma
|
22302227
|
887
|
kallikrein-related peptide 4 (KLK4)
|
mRNA
|
Humans
|
Downregulated in genistein treated patients compared to placebo treated
|
Predictive
|
Treated with Placebo Vs Treated with Genistein (30mg capsule)
|
p=0.033
|
Tissue
|
22397815
|
897
|
Macroglobulin α2 ; HP protein; CLU precursor; Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region;
|
Protein
|
Humans
|
Upregulated [>1.5 fold]: (Macroglobulin α2 ; HP protein; CLU precursor; ) Downregulated: [1.5 fold] (Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region;)
|
Predictive
|
Before and after androgen ablation therapy (AAT)
|
p<0.01
|
Serum
|
22496929
|
898
|
Transthyretin (TTR)
|
Protein
|
Humans
|
Downregulated (1.58 fold ) in Post AAT patients
|
Predictive
|
Before and after androgen ablation therapy (AAT)
|
p<0.01
|
Serum
|
22496929
|
899
|
Clusterin (CLU)
|
Protein
|
Humans
|
Upregulated (1.51 fold ) in Post AAT patients
|
Predictive
|
Before and after androgen ablation therapy (AAT)
|
p<0.01
|
Serum
|
22496929
|
920
|
Deoxycarnitine; Acetylcarnitine; Hexanoylcarnitine; Octanoylcarnitine; Decanoylcarnitine; Laurylcarnitine; Palmitoylcarnitine; Stearoylcarnitine; Oleoylcarnitine; 3-hydroxybutyrate (BHBA); Acetoacetate; Dodecanedioate; Octadecanedioate;
|
Metabolites
|
Humans
|
Differentially expressed [ Deoxycarnitine (0.89 fold); Acetylcarnitine (0.80 fold); Hexanoylcarnitine (0.80 fold_; Octanoylcarnitine (0.72 fold); Decanoylcarnitine (0.71 fold); Laurylcarnitine (0.65 fold); Palmitoylcarnitine (0.82 fold0; Stearoylcarnitine (0.77 fold); Oleoylcarnitine (0.88 fold); 3-hydroxybutyrate (BHBA) (0.36 fold); Acetoacetate (0.52 fold); Dodecanedioate (0.80 fold); Octadecanedioate (0.73 fold);]
|
Predictive
|
Effect of Androgen deprivation therapy (ADT) baseline to 3 months
|
<0.05
|
Plasma
|
22589396
|
1032
|
C-terminal telopeptide
|
Protein
|
Humans
|
Downregulated in patients with PCa treated with with Risedronate (Placebo: 138.16± 26.71; Risedronate: 18.24 ± 22.38)
|
Predictive
|
Placebo vs Risedronate (after 24 months)
|
p =0.0014
|
Serum
|
23265571
|
1033
|
Bone-specific alkaline phosphatase
|
Protein
|
Humans
|
Downregulated in patients with PCa treated with with Risedronate (Placebo: 60.29 ± 10.28; Risedronate: 9.94 ± 6.95)
|
Predictive
|
Placebo vs Risedronate (after 24 months)
|
p =0.0002
|
Serum
|
23265571
|
1034
|
N-Mid-Osteocalcin
|
Protein
|
Humans
|
Downregulated in patients with PCa treated with with Risedronate (Placebo: 100.35 ± 30.4; Risedronate: 18.85 ± 10.8)
|
Predictive
|
Placebo vs Risedronate (after 24 months)
|
p =0.0173
|
Serum
|
23265571
|
1057
|
Testosterone
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 4.62 ±1.48; After: 0.15 ± 0.1)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p<0.001
|
Serum
|
23374809
|
1058
|
Dihydrotestosterone (DHT)
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 0.88 ±0.41 ; After: 0.05 ± 012)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p<0.001
|
Serum
|
23374809
|
1059
|
Dehydroepiandrosterone sulfate (DHEA-S)
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 133.3 ±63.8; After: 83.4 ± 51.4)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p<0.001
|
Serum
|
23374809
|
1060
|
Androstenedione
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 1.6 ±0.61 ; After: 0.83 ± 0.42)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p<0.001
|
Serum
|
23374809
|
1061
|
3α-diol-G
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 26.4 ±6.9 ; After: 5.4 ± 7.1)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p<0.001
|
Serum
|
23374809
|
1062
|
Insulin-like growth factor 1 (IGF-I)
|
Metabolites
|
Humans
|
Upregulated with Androgen Deprivation Therapy (Before: 19.9 ±7.7 ; After: 22.2 ±9.1 )
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p=0.001
|
Serum
|
23374809
|
1063
|
1,25(OH)2D
|
Metabolites
|
Humans
|
Downregulated with Androgen Deprivation Therapy (Before: 66.2 ±4.2 ; After: 59.7 ± 4.0)
|
Predictive
|
Before and after androgen Deprivation therapy (ADT)
|
p=0.008
|
Serum
|
23374809
|
1124
|
β-CTX (β-isomer of carboxiterminal telopeptide of collagen I)
|
Protein
|
Humans
|
NA
|
Predictive
|
Survival Vs No Survival after treatment with zoledronic acid
|
p = 0.0049
|
Serum
|
23722472
|
1125
|
P1NP (aminoterminal propeptide of procollagen I)
|
Protein
|
Humans
|
NA
|
Predictive
|
Survival Vs No Survival after treatment with zoledronic acid
|
p = 0.0139
|
Serum
|
23722472
|
1149
|
Insulin Like Growth Factor Binding Proteins (IGFBP-3)
|
Protein
|
Humans
|
Upregulated in Intervention Group
|
Predictive
|
Intervention Vs Control Group
|
p = 0.002
|
Serum
|
23775525
|
1248
|
Thrombospondin-1 [TSP-1]
|
Protein
|
Humans
|
Increased levels indicate better overall survival in Tasquinimod arm
|
Predictive
|
Overall Survival in Tasquinimod Vs Overall Survival in Placebo arm
|
p=0.034
|
Plasma
|
24255071
|
1344
|
Bone Alkaline Phosphatase [BAP]
|
Protein
|
Humans
|
Upregulated (Estimate: 0.16)
|
Predictive
|
Atrasentan Vs Placebo Arm at baseline to week 9
|
p<0.001
|
Serum
|
24565955
|
1345
|
C-terminal of type 1 collagen [CICP]
|
Protein
|
Humans
|
Downregulated (Estimate: 0.16)
|
Predictive
|
Atrasentan Vs Placebo Arm at baseline to week 9
|
p<0.001
|
Serum
|
24565955
|
1346
|
Pyridinoline [PYD]
|
Protein
|
Humans
|
Downregulated (Estimate: 0.16)
|
Predictive
|
Atrasentan Vs Placebo Arm at baseline to week 9
|
p<0.001
|
Serum
|
24565955
|
1384
|
mir-200c
|
miRNA
|
Humans
|
Upregulated in Non Responders (Median NR/median R): 1.6 fold
|
Predictive
|
PSA responder Vs Non Responder (Pre Docetaxel levels)
|
p=0.02
|
Blood
|
24714754
|
1385
|
mir-200b
|
miRNA
|
Humans
|
Upregulated in Non Responders (Median NR/median R): 2.7 fold
|
Predictive
|
PSA responder Vs Non Responder (Pre Docetaxel levels)
|
p=0.02
|
Blood
|
24714754
|
1386
|
mir-146a
|
miRNA
|
Humans
|
Downregulated in Non Responders (Median NR/median R): 1.4 fold
|
Predictive
|
PSA responder Vs Non Responder (Pre Docetaxel levels)
|
p=0.05
|
Blood
|
24714754
|
1387
|
mir-222
|
miRNA
|
Humans
|
Upregulated after Docetaxel treatment in Responders (1.4 fold) and Downregulated after Docetaxel treatment in Non Responders (1.1 fold)
|
Predictive
|
PSA responder Vs Non Responder -Post Docetaxel Change
|
p=0.01
|
Blood
|
24714754
|
1388
|
mir-301b
|
miRNA
|
Humans
|
Upregulated after Docetaxel treatment in Responders (1.1 fold) and in Non Responders (1.6 fold)
|
Predictive
|
PSA responder Vs Non Responder -Post Docetaxel Change
|
p=0.04
|
Blood
|
24714754
|
1389
|
mir-20a
|
miRNA
|
Humans
|
Upregulated after Docetaxel treatment in Responders (1.6 fold) and in Non Responders (1.1 fold)
|
Predictive
|
PSA responder Vs Non Responder -Post Docetaxel Change
|
p=0.04
|
Blood
|
24714754
|
1390
|
mir-200c + mir-200b + mir-146a
|
miRNA
|
Humans
|
NA
|
Predictive
|
PSA responder Vs Non Responder (Pre Docetaxel levels)
|
p=0.001
|
Blood
|
24714754
|
1391
|
mir-222 + mir-301b + mir-20a
|
miRNA
|
Humans
|
NA
|
Predictive
|
PSA responder Vs Non Responder -Post Docetaxel Change
|
p = 0.02
|
Blood
|
24714754
|
1392
|
mir-200c + mir-200b + mir-146a+ mir-222 + mir-301b + mir-20a
|
miRNA
|
Humans
|
NA
|
Predictive
|
PSA responder Vs Non Responder (Pre Docetaxel levels and Post Docetaxel Changes)
|
p=0.001
|
Blood
|
24714754
|
1394
|
Testosterone
|
Hormone
|
Humans
|
Lower levels in Non Responders
|
Predictive
|
PSA Responders Vs Non Responder
|
p=0.0196
|
Plasma
|
24722180
|
1453
|
Glutathione (GSH)
|
Protein
|
Humans
|
Downregulated after treatment with SeMet for 9 months (0.22 ± 0.07 change from baseline)
|
Predictive
|
Baseline Vs 9 months later after treatment with SeMet
|
p<0.05
|
Blood
|
24938534
|
1728
|
HA: Hyaluronic acid
|
Metabolites
|
Humans
|
Upregulated in Patient Reclassification
|
Predictive
|
Before and After Surgery Levels
|
p=0.029
|
Serum
|
30516927
|